A5100738764- Hepatocellular Carcinoma Treatment and Prognosis
- PI3K/AKT/mTOR signaling in cancer
- Cancer Mechanisms and Therapy
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Liver Disease Diagnosis and Treatment
- RNA modifications and cancer
- Adrenal and Paraganglionic Tumors
- Endoplasmic Reticulum Stress and Disease
- Cancer, Lipids, and Metabolism
- Advanced Glycation End Products research
- Microbial Inactivation Methods
- Ferroptosis and cancer prognosis
- Cancer, Hypoxia, and Metabolism
- Inflammatory mediators and NSAID effects
- Sirtuins and Resveratrol in Medicine
- Cancer-related molecular mechanisms research
- Glycosylation and Glycoproteins Research
Korea University Medical Center
2022
Kyungpook National University Hospital
2010
Samsung Medical Center
2010
Pohang University of Science and Technology
2010
Sungkyunkwan University
2010
We investigated the expression of high-mobility group box 2 (HMGB2) in patients with hepatocellular carcinoma (HCC) and its clinical effects underlying mechanisms.HMGB2 mRNA levels were measured 334 HCC by real-time reverse transcription-PCR HMGB2 protein 173 immunohistochemical studies. The level was Western blotting for three cell lines. To clarify precise role on proliferation, we did vitro analysis vectors small interfering RNAs.HMGB2 significantly higher than noncancerous surrounding...
Hepatocellular carcinoma is one of the most lethal cancers worldwide. More accurate stratification patients at risk necessary to improve its clinical management. As epithelial–mesenchymal transition critical for invasiveness and metastasis human cancers, we investigated expression profiles 12 genes related through a real‐time polymerase chain reaction. From univariate Cox analysis training cohort 128 hepatocellular patients, four candidate (E‐cadherin [ CDH1 ], inhibitor DNA binding 2 ID2...
Background The effectiveness of molecular targeted agents is modest in hepatocellular carcinoma (HCC). Efficacy therapies has been better cancer patients with high expression actionable molecules defined as cognate target molecules. However, patient stratification based on the dictating drugs remained understudied HCC. Experimental Design & Results Paired tumor and non-tumoral tissues derived from a total 130 HCC were studied. Real-time RT-PCR was used to analyze mRNA tissues. levels EGFR,...
OncoHepa test is a multigene expression profile developed for assessment of hepatocellular carcinoma (HCC) prognosis. Multiplication α-FP, des-γ-carboxy prothrombin (DCP) and tumor volume (TV) gives the α-FP-DCP-volume (ADV) score, which also HCC prognosis.The predictive powers ADV score were validated in 35 patients who underwent curative hepatic resection naïve solitary HCCs ≤5 cm.Median diameter was 3.0 cm. Tumor recurrence patient survival rates 28.6% 100% at 1 year, 48.6% 82.9% 3 years,...
Despite a low risk of liver failure and preserved function, non-cirrhotic hepatocellular carcinoma (HCC) has poor prognosis. In the current study, we evaluated an active regulator SIRT1 (AROS) as prognostic biomarker in HCC. mRNA levels AROS were measured tumor non-tumor tissues obtained from 283 HCC patients. expression was exclusively up-regulated recurrent patients (P = 0.015) also irrespective stage < 0.001) or BCLC 0.001). High statistically significantly associated with 0.001), 0.007),...
339 Background: Irreversible electroporation (IRE) is a new destructive technique that removes undesirable tissues using an electric field. Main mechanism of IRE through the creation permanent, nano-sized pores on cell membranes, resulting in death. It poses, however, one technical challenge as contractions smooth muscle gastrointestinal tract may prevent from effectively electroporate cell. The present study aims to demonstrate applicability this newly designed endoscopic balloon-type...